IBDEI1XP ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30896,0)
;;=N03.1^^123^1597^17
;;^UTILITY(U,$J,358.3,30896,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30896,1,3,0)
;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
;;^UTILITY(U,$J,358.3,30896,1,4,0)
;;=4^N03.1
;;^UTILITY(U,$J,358.3,30896,2)
;;=^5015522
;;^UTILITY(U,$J,358.3,30897,0)
;;=N03.2^^123^1597^14
;;^UTILITY(U,$J,358.3,30897,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30897,1,3,0)
;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
;;^UTILITY(U,$J,358.3,30897,1,4,0)
;;=4^N03.2
;;^UTILITY(U,$J,358.3,30897,2)
;;=^5015523
;;^UTILITY(U,$J,358.3,30898,0)
;;=N03.3^^123^1597^15
;;^UTILITY(U,$J,358.3,30898,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30898,1,3,0)
;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
;;^UTILITY(U,$J,358.3,30898,1,4,0)
;;=4^N03.3
;;^UTILITY(U,$J,358.3,30898,2)
;;=^5015524
;;^UTILITY(U,$J,358.3,30899,0)
;;=N03.4^^123^1597^13
;;^UTILITY(U,$J,358.3,30899,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30899,1,3,0)
;;=3^Chr nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
;;^UTILITY(U,$J,358.3,30899,1,4,0)
;;=4^N03.4
;;^UTILITY(U,$J,358.3,30899,2)
;;=^5015525
;;^UTILITY(U,$J,358.3,30900,0)
;;=N03.5^^123^1597^16
;;^UTILITY(U,$J,358.3,30900,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30900,1,3,0)
;;=3^Chr nephritic syndrome w/ diffuse mesangiocap glomrlneph
;;^UTILITY(U,$J,358.3,30900,1,4,0)
;;=4^N03.5
;;^UTILITY(U,$J,358.3,30900,2)
;;=^5015526
;;^UTILITY(U,$J,358.3,30901,0)
;;=N03.6^^123^1597^11
;;^UTILITY(U,$J,358.3,30901,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30901,1,3,0)
;;=3^Chr nephritic syndrome w/ dense deposit disease
;;^UTILITY(U,$J,358.3,30901,1,4,0)
;;=4^N03.6
;;^UTILITY(U,$J,358.3,30901,2)
;;=^5015527
;;^UTILITY(U,$J,358.3,30902,0)
;;=N03.7^^123^1597^12
;;^UTILITY(U,$J,358.3,30902,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30902,1,3,0)
;;=3^Chr nephritic syndrome w/ diffuse crescentic glomrlneph
;;^UTILITY(U,$J,358.3,30902,1,4,0)
;;=4^N03.7
;;^UTILITY(U,$J,358.3,30902,2)
;;=^5015528
;;^UTILITY(U,$J,358.3,30903,0)
;;=N03.8^^123^1597^19
;;^UTILITY(U,$J,358.3,30903,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30903,1,3,0)
;;=3^Chr nephritic syndrome w/ other morphologic changes
;;^UTILITY(U,$J,358.3,30903,1,4,0)
;;=4^N03.8
;;^UTILITY(U,$J,358.3,30903,2)
;;=^5015529
;;^UTILITY(U,$J,358.3,30904,0)
;;=N03.9^^123^1597^20
;;^UTILITY(U,$J,358.3,30904,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30904,1,3,0)
;;=3^Chr nephritic syndrome w/ unsp morphologic changes
;;^UTILITY(U,$J,358.3,30904,1,4,0)
;;=4^N03.9
;;^UTILITY(U,$J,358.3,30904,2)
;;=^5015530
;;^UTILITY(U,$J,358.3,30905,0)
;;=N04.0^^123^1597^59
;;^UTILITY(U,$J,358.3,30905,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30905,1,3,0)
;;=3^Nephrotic syndrome w/ minor glomerular abnormality
;;^UTILITY(U,$J,358.3,30905,1,4,0)
;;=4^N04.0
;;^UTILITY(U,$J,358.3,30905,2)
;;=^5015531
;;^UTILITY(U,$J,358.3,30906,0)
;;=N04.1^^123^1597^58
;;^UTILITY(U,$J,358.3,30906,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30906,1,3,0)
;;=3^Nephrotic syndrome w/ focal & segmental glomerular lesions
;;^UTILITY(U,$J,358.3,30906,1,4,0)
;;=4^N04.1
;;^UTILITY(U,$J,358.3,30906,2)
;;=^5015532
;;^UTILITY(U,$J,358.3,30907,0)
;;=N04.2^^123^1597^55
;;^UTILITY(U,$J,358.3,30907,1,0)
;;=^358.31IA^4^2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XP 3751 printed Nov 22, 2024@17:28 Page 2
IBDEI1XP ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30896,0)
+2 ;;=N03.1^^123^1597^17
+3 ;;^UTILITY(U,$J,358.3,30896,1,0)
+4 ;;=^358.31IA^4^2
+5 ;;^UTILITY(U,$J,358.3,30896,1,3,0)
+6 ;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
+7 ;;^UTILITY(U,$J,358.3,30896,1,4,0)
+8 ;;=4^N03.1
+9 ;;^UTILITY(U,$J,358.3,30896,2)
+10 ;;=^5015522
+11 ;;^UTILITY(U,$J,358.3,30897,0)
+12 ;;=N03.2^^123^1597^14
+13 ;;^UTILITY(U,$J,358.3,30897,1,0)
+14 ;;=^358.31IA^4^2
+15 ;;^UTILITY(U,$J,358.3,30897,1,3,0)
+16 ;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
+17 ;;^UTILITY(U,$J,358.3,30897,1,4,0)
+18 ;;=4^N03.2
+19 ;;^UTILITY(U,$J,358.3,30897,2)
+20 ;;=^5015523
+21 ;;^UTILITY(U,$J,358.3,30898,0)
+22 ;;=N03.3^^123^1597^15
+23 ;;^UTILITY(U,$J,358.3,30898,1,0)
+24 ;;=^358.31IA^4^2
+25 ;;^UTILITY(U,$J,358.3,30898,1,3,0)
+26 ;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
+27 ;;^UTILITY(U,$J,358.3,30898,1,4,0)
+28 ;;=4^N03.3
+29 ;;^UTILITY(U,$J,358.3,30898,2)
+30 ;;=^5015524
+31 ;;^UTILITY(U,$J,358.3,30899,0)
+32 ;;=N03.4^^123^1597^13
+33 ;;^UTILITY(U,$J,358.3,30899,1,0)
+34 ;;=^358.31IA^4^2
+35 ;;^UTILITY(U,$J,358.3,30899,1,3,0)
+36 ;;=3^Chr nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
+37 ;;^UTILITY(U,$J,358.3,30899,1,4,0)
+38 ;;=4^N03.4
+39 ;;^UTILITY(U,$J,358.3,30899,2)
+40 ;;=^5015525
+41 ;;^UTILITY(U,$J,358.3,30900,0)
+42 ;;=N03.5^^123^1597^16
+43 ;;^UTILITY(U,$J,358.3,30900,1,0)
+44 ;;=^358.31IA^4^2
+45 ;;^UTILITY(U,$J,358.3,30900,1,3,0)
+46 ;;=3^Chr nephritic syndrome w/ diffuse mesangiocap glomrlneph
+47 ;;^UTILITY(U,$J,358.3,30900,1,4,0)
+48 ;;=4^N03.5
+49 ;;^UTILITY(U,$J,358.3,30900,2)
+50 ;;=^5015526
+51 ;;^UTILITY(U,$J,358.3,30901,0)
+52 ;;=N03.6^^123^1597^11
+53 ;;^UTILITY(U,$J,358.3,30901,1,0)
+54 ;;=^358.31IA^4^2
+55 ;;^UTILITY(U,$J,358.3,30901,1,3,0)
+56 ;;=3^Chr nephritic syndrome w/ dense deposit disease
+57 ;;^UTILITY(U,$J,358.3,30901,1,4,0)
+58 ;;=4^N03.6
+59 ;;^UTILITY(U,$J,358.3,30901,2)
+60 ;;=^5015527
+61 ;;^UTILITY(U,$J,358.3,30902,0)
+62 ;;=N03.7^^123^1597^12
+63 ;;^UTILITY(U,$J,358.3,30902,1,0)
+64 ;;=^358.31IA^4^2
+65 ;;^UTILITY(U,$J,358.3,30902,1,3,0)
+66 ;;=3^Chr nephritic syndrome w/ diffuse crescentic glomrlneph
+67 ;;^UTILITY(U,$J,358.3,30902,1,4,0)
+68 ;;=4^N03.7
+69 ;;^UTILITY(U,$J,358.3,30902,2)
+70 ;;=^5015528
+71 ;;^UTILITY(U,$J,358.3,30903,0)
+72 ;;=N03.8^^123^1597^19
+73 ;;^UTILITY(U,$J,358.3,30903,1,0)
+74 ;;=^358.31IA^4^2
+75 ;;^UTILITY(U,$J,358.3,30903,1,3,0)
+76 ;;=3^Chr nephritic syndrome w/ other morphologic changes
+77 ;;^UTILITY(U,$J,358.3,30903,1,4,0)
+78 ;;=4^N03.8
+79 ;;^UTILITY(U,$J,358.3,30903,2)
+80 ;;=^5015529
+81 ;;^UTILITY(U,$J,358.3,30904,0)
+82 ;;=N03.9^^123^1597^20
+83 ;;^UTILITY(U,$J,358.3,30904,1,0)
+84 ;;=^358.31IA^4^2
+85 ;;^UTILITY(U,$J,358.3,30904,1,3,0)
+86 ;;=3^Chr nephritic syndrome w/ unsp morphologic changes
+87 ;;^UTILITY(U,$J,358.3,30904,1,4,0)
+88 ;;=4^N03.9
+89 ;;^UTILITY(U,$J,358.3,30904,2)
+90 ;;=^5015530
+91 ;;^UTILITY(U,$J,358.3,30905,0)
+92 ;;=N04.0^^123^1597^59
+93 ;;^UTILITY(U,$J,358.3,30905,1,0)
+94 ;;=^358.31IA^4^2
+95 ;;^UTILITY(U,$J,358.3,30905,1,3,0)
+96 ;;=3^Nephrotic syndrome w/ minor glomerular abnormality
+97 ;;^UTILITY(U,$J,358.3,30905,1,4,0)
+98 ;;=4^N04.0
+99 ;;^UTILITY(U,$J,358.3,30905,2)
+100 ;;=^5015531
+101 ;;^UTILITY(U,$J,358.3,30906,0)
+102 ;;=N04.1^^123^1597^58
+103 ;;^UTILITY(U,$J,358.3,30906,1,0)
+104 ;;=^358.31IA^4^2
+105 ;;^UTILITY(U,$J,358.3,30906,1,3,0)
+106 ;;=3^Nephrotic syndrome w/ focal & segmental glomerular lesions
+107 ;;^UTILITY(U,$J,358.3,30906,1,4,0)
+108 ;;=4^N04.1
+109 ;;^UTILITY(U,$J,358.3,30906,2)
+110 ;;=^5015532
+111 ;;^UTILITY(U,$J,358.3,30907,0)
+112 ;;=N04.2^^123^1597^55
+113 ;;^UTILITY(U,$J,358.3,30907,1,0)
+114 ;;=^358.31IA^4^2
